Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
1.
Braz. j. infect. dis ; 22(3): 193-201, May-June 2018. tab, graf
Artigo em Inglês | LILACS | ID: biblio-974216

RESUMO

ABSTRACT Background In people living with HIV, much is known about chronic kidney disease, defined as a glomerular filtration rate under 60 mL/min. However, there is scarce data about prevalence and risk factors for milder impairment (60-89 mL/min). Objective The present study aims to assess the influence of sex, antiretroviral therapy, and classical risk factors on the occurrence of mild decreased renal function in a large Spanish cohort of HIV-infected patients. Methods Cross-sectional, single center study, including all adult HIV-1-infected patients under antiretroviral treatment with at least two serum creatinine measures during 2014, describing the occurrence of and the risk factors for mildly decreased renal function (eGFR by CKD-EPI creatinine equation of 60-89 mL/min). Results Among the 4337 patients included, the prevalence rate of mildly reduced renal function was 25%. Independent risk factors for this outcome were age older than 50 years (OR 3.03, 95% CI 2.58-3.55), female sex (OR 1.23, 95% CI 1.02-1.48), baseline hypertension (OR 1.57, 95% CI 1.25-1.97) or dyslipidemia (OR 1.48, 95% CI 1.17-1.87), virologic suppression (OR 1.88, 95% CI 1.39-2.53), and exposure to tenofovir disoproxil-fumarate (OR 1.67, 95% CI 1.33-2.08) or ritonavir-boosted protease-inhibitors (OR 1.19, 95% CI 1.03-1.39). Conclusions Females and patients over 50 seem to be more vulnerable to renal impairment. Potentially modifiable risk factors and exposure to tenofovir disoproxil-fumarate or ritonavir-boosted protease-inhibitors are present even in earlier stages of chronic kidney dysfunction. It remains to be determined whether early interventions including antiretroviral therapy changes (tenofovir alafenamide, cobicistat) or improving comorbidities management will improve the course of chronic kidney disease.


Assuntos
Humanos , Masculino , Feminino , Adolescente , Adulto , Pessoa de Meia-Idade , Idoso , Idoso de 80 Anos ou mais , Adulto Jovem , Infecções por HIV/complicações , Infecções por HIV/tratamento farmacológico , Infecções por HIV/epidemiologia , Fármacos Anti-HIV/efeitos adversos , Falência Renal Crônica/etiologia , Falência Renal Crônica/epidemiologia , Espanha/epidemiologia , Comorbidade , Fatores Sexuais , Prevalência , Estudos Transversais , Fatores de Risco , Fatores Etários , Resultado do Tratamento , Estatísticas não Paramétricas , Medição de Risco , Carga Viral , Terapia Antirretroviral de Alta Atividade/efeitos adversos , Taxa de Filtração Glomerular
2.
Actual. SIDA ; 16(61): 88-102, set. 2008. tab
Artigo em Espanhol | LILACS | ID: lil-522008

RESUMO

Actualmente la enfermedad hepática es una de las causas más importantes de morbilidad y mortalidad en los pacientes con infección por VIH. La supervivencia de los pacientes con enfermedad hepática terminal es más corta comparada con la de las personas no infectadas. La infección por VIH ha dejado de ser una contraindicación para el trasplante de órganos sólidos...


Currently, liver disease is one of the most important cause of morbidity and mortality in HIV-1 infected patients. Survival of HIV-coinfected patients with end-stage liver disease (ESLD) is poor and shorter than that of the non-HIV-infected population. HIV infections is no longer a contraindication to solid organ transplantation...


Assuntos
Humanos , Terapia Antirretroviral de Alta Atividade , Cirrose Hepática/mortalidade , Hepacivirus , Vírus da Hepatite B , HIV-1 , Infecções por HIV/complicações , Imunoglobulinas/uso terapêutico , Transplante de Fígado/patologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA